Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo

被引:15
|
作者
Xie, Qi [1 ]
Wu, Min-Yi [1 ]
Zhang, Ding-Xuan [1 ]
Yang, Yi-Ming [1 ]
Wang, Bao-Shuai [1 ]
Zhang, Jing [2 ]
Xu, Jin [3 ]
Zhong, Wei-De [4 ]
Hu, Jia-Ni [5 ]
机构
[1] Guangzhou Med Univ, Dept Med Imaging, Nansha Cent Hosp, Guangzhou Peoples Hosp 1, Guangzhou 511457, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Dept Pathol, Ctr Canc, Guangzhou 510080, Guangdong, Peoples R China
[3] Guangzhou Med Univ, Dept Pathol, Guangzhou Peoples Hosp 1, Guangzhou 510180, Guangdong, Peoples R China
[4] Guangzhou Med Univ, Clin Mol Med & Mol Diagnost Lab, Guangzhou Peoples Hosp 1, Guangzhou 510180, Guangdong, Peoples R China
[5] Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA
关键词
Human colon cancer; Multidrug resistance; 5-Fluorouracil; Recombinant adenovirus-mediated p53; Xenografts in nude mice; TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; MULTIDRUG-RESISTANCE; THYMIDYLATE SYNTHASE; DRUG-RESISTANCE; BREAST-CANCER; CELL-LINE; 5-FLUOROURACIL; THERAPY; CARCINOMA;
D O I
10.3748/wjg.v22.i32.7342
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To investigate the anticancer effect of a recom-binant adenovirus-mediated p53 (rAd-p53) combined with 5-fluorouracil (5-FU) in human colon cancer resistant to 5-FU in vivo and the mechanism of rAd-p53 in reversal of 5-FU resistance. METHODS Nude mice bearing human colon cancer SW480/5FU (5-FU resistant) were randomly assigned to four groups (n = 25 each): control group, 5-FU group, rAd-p53 group, and rAd-p53 + 5-FU group. At 24 h, 48 h, 72 h, 120 h and 168 h after treatment, 5 mice were randomly selected from each group and sacrificed using an overdose of anesthetics. The tumors were removed and the protein expressions of p53, protein kinase C (PKC), permeability-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) (Western blot) and apoptosis (TUNEL) were determined. RESULTS The area ratios of tumor cell apoptosis were larger in the rAd/p53 + 5-FU group than that in the control, 5-FU and rAd/p53 groups (P < 0.05), and were larger in the rAd/p53 group than that of the control group (P < 0.05) and the 5-FU group at more than 48 h (P < 0.05). The p53 expression was higher in the rAd/p53 and the rAd/p53 + 5-FU groups than that of the control and 5-FU groups (P < 0.05), and were higher in the rAd/p53 + 5-FU group than that of the rAd/p53 group (P < 0.05). Overexpression of PKC, P-gp and MRP1 was observed in the 5-FU and control groups. In the rAd/p53 + 5-FU group, the expression of P-gp and MRP1 was lower that of the control and 5-FU groups (P < 0.05), and the expression of PKC was lower than that of the control, 5-FU and rAd/p53 groups at more than 48 h (P < 0.05). In the rAd/p53 group, the expression of P-gp and MRP1 was lower that of the control and 5-FU groups at more than 48 h (P < 0.05), and the expression of PKC was lower than that of the control and 5-FU groups at more than 120 h (P < 0.05). CONCLUSION 5-FU combined with rAd-p53 has a synergistic anticancer effect in SW480/5-FU (5-FU resistance), which contributes to reversal 5-FU resistance.
引用
收藏
页码:7342 / 7352
页数:11
相关论文
共 50 条
  • [31] 5-fluorouracil(5-FU)-induced apoptosis in human gastric cancer cell lines; Role of P53, P21/Waf1
    Osaki, M
    Tatebe, S
    Goto, A
    Shomori, K
    Adachi, H
    Ito, H
    RECENT ADVANCES IN GASTROENTEROLOGICAL CARCINOGENESIS I, 1996, : 433 - 437
  • [32] Synergetic effects of retrovirus IFN-α gene transfer and 5-FU on apoptosis of colon cancer cells
    Sabaawy, HE
    Farley, T
    Ahmed, T
    Feldman, E
    Abraham, NG
    ACTA HAEMATOLOGICA, 1999, 101 (02) : 82 - 88
  • [33] S-1, an oral fluoropyrimidine, enhances radiation. response of DLD-1/FU human colon cancer xenografts resistant to 5-FU
    Nakata, Eiko
    Fukushima, Masakazu
    Takai, Yoshihiro
    Nemoto, Kenji
    Ogawa, Yoshihiro
    Nomiya, Takuma
    Nakamura, Yasuhiro
    Milas, Luka
    Yamada, Shogo
    ONCOLOGY REPORTS, 2006, 16 (03) : 465 - 471
  • [34] BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers
    Lavitrano, Marialuisa
    Ianzano, Leonarda
    Bonomo, Sara
    Cialdella, Annamaria
    Cerrito, Maria Grazia
    Pisano, Fabio
    Missaglia, Carola
    Giovannoni, Roberto
    Romano, Gabriele
    McLean, Chelsea M.
    Voest, Emile E.
    D'Amato, Filomena
    Noli, Barbara
    Ferri, Gian Luca
    Agostini, Marco
    Pucciarelli, Salvatore
    Helin, Kristian
    Leone, Biagio E.
    Canzonieri, Vincenzo
    Grassilli, Emanuela
    JOURNAL OF PATHOLOGY, 2020, 250 (02): : 134 - 147
  • [35] Changes in 5-fluorouracil (5-FU) metabolism-relating-gene expressions and sensitivity to 5-FU after 5-aza-2′-deoxycitizine treatment in human gastrointestinal cancer cell lines
    Odashima, Yoko
    Terashima, Masanori
    Otani, Satoshi
    Kashimura, Seigo
    Soeta, Nobutoshi
    Hoshino, Yutaka
    Kogure, Michihiko
    Gotoh, Mitsukazu
    CANCER RESEARCH, 2006, 66 (08)
  • [36] Effect of apatinib combined with 5-fluorouracil (5-FU) on proliferation, apoptosis and invasiveness of gastric cancer cells
    Zhao, P.
    Zhang, J.
    Pang, X.
    Zhao, L.
    Li, Q.
    Cao, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism
    Eiji Sasaki
    Kazunari Tominaga
    Hikaru Kuwamura
    Toshio Watanabe
    Yasuhiro Fujiwara
    Nobuhide Oshitani
    Kazuhide Higuchi
    Tetsuo Arakawa
    Journal of Gastroenterology, 2007, 42 : 816 - 822
  • [38] 5-FU targets rpL3 to induce mitochondrial apoptosis via cystathionine-β-synthase in colon cancer cells lacking p53
    Pagliara, Valentina
    Saide, Assunta
    Mitidieri, Emma
    Bianca, Roberta d'Emmanuele di Villa
    Sorrentino, Raffaella
    Russo, Giulia
    Russo, Annapina
    ONCOTARGET, 2016, 7 (31) : 50333 - 50348
  • [39] Combined therapeutic effectiveness of retrovirus-mediated interferon-α gene transfer and 5-FU on colon cancer cells.
    El-Sabaawy, H
    Feldman, E
    Ikehara, S
    Adachi, Y
    Abraham, NG
    Ahmed, T
    BLOOD, 1998, 92 (10) : 384B - 384B
  • [40] Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism
    Sasaki, Eiji
    Tominaga, Kazunari
    Kuwamura, Hikaru
    Watanabe, Toshio
    Fujiwara, Yasuhiro
    Oshitani, Nobuhide
    Higuchi, Kazuhide
    Arakawa, Tetsuo
    JOURNAL OF GASTROENTEROLOGY, 2007, 42 (10) : 816 - 822